These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22585410)

  • 21. Heterogeneous growth bent-cable models for time-to-event and longitudinal data: application to AIDS studies.
    Dagne GA
    J Biopharm Stat; 2018; 28(6):1216-1230. PubMed ID: 29953318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Roaming through methodology. XXXVI. Likelihood ratios and Bayes' rule].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2001 Dec; 145(50):2421-4. PubMed ID: 11776667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesians in clinical trials: asleep at the switch.
    Moyé LA
    Stat Med; 2008 Feb; 27(4):469-82; discussion 483-9. PubMed ID: 17573687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian statistics in medical devices: innovation sparked by the FDA.
    Campbell G
    J Biopharm Stat; 2011 Sep; 21(5):871-87. PubMed ID: 21830920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biostatistical applications in epidemiology.
    Kier KL
    Pharmacotherapy; 2011 Jan; 31(1):9-22. PubMed ID: 21182354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis in the design and monitoring of clinical trials.
    DerSimonian R
    Stat Med; 1996 Jun; 15(12):1237-48; discussion 1249-52. PubMed ID: 8817798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Considerations on what constitutes a 'qualified statistician' in regulatory guidelines.
    Gerlinger C; Edler L; Friede T; Kieser M; Nakas CT; Schumacher M; Seldrup J; Victor N
    Stat Med; 2012 May; 31(11-12):1303-5. PubMed ID: 21948351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating treatment effects in clinical crossover trials.
    Grieve A; Senn S
    J Biopharm Stat; 1998 May; 8(2):191-233; discussion 235-47. PubMed ID: 9598420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical Methods for Cardiovascular Researchers.
    Moyé L
    Circ Res; 2016 Feb; 118(3):439-53. PubMed ID: 26846639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Commentary on 'Measurement in clinical trials: a neglected issue for statisticians?'.
    Wittes J
    Stat Med; 2009 Nov; 28(26):3220-2; discussion 3223-5. PubMed ID: 19842097
    [No Abstract]   [Full Text] [Related]  

  • 32. Proceedings of the University of Pennsylvania annual conference on statistical issues in clinical trials: early, translational and proof of concept studies: the 'go/no go' decisions.
    Ellenberg JH; Mick R; Ellenberg SS
    Stat Med; 2010 May; 29(10):1059-60. PubMed ID: 20419757
    [No Abstract]   [Full Text] [Related]  

  • 33. Analyzing and Interpreting Clinical Trials.
    Spino C
    Gastroenterology; 2016 Apr; 150(4):797-800. PubMed ID: 26924090
    [No Abstract]   [Full Text] [Related]  

  • 34. Literature review: January-March 2008.
    Patterson SD; Carroll K
    Pharm Stat; 2008; 7(2):147-9. PubMed ID: 18428118
    [No Abstract]   [Full Text] [Related]  

  • 35. Meta-regression with partial information on summary trial or patient characteristics.
    Hemming K; Hutton JL; Maguire MG; Marson AG
    Stat Med; 2010 May; 29(12):1312-24. PubMed ID: 20087842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Paradigms and pragmatism].
    Healy MJ
    Rev Epidemiol Sante Publique; 1999 Apr; 47(2):185-9. PubMed ID: 10367305
    [No Abstract]   [Full Text] [Related]  

  • 37. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group.
    Thabane L; Wells G; Cook R; Platt R; Pogue J; Pullenayegum E; Matthews D; McCready T; Devereaux PJ; Cairns JA; Yusuf S;
    Trials; 2011 Feb; 12():48. PubMed ID: 21332987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpreting and reporting clinical trials with results of borderline significance.
    Hackshaw A; Kirkwood A
    BMJ; 2011 Jul; 343():d3340. PubMed ID: 21727163
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.